München
10.07.26 | 08:01
0,076 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.06. | Klaria Pharma Holding AB: Report from the Annual General Meeting of Klaria Pharma Holding AB (publ) | 279 | GlobeNewswire (Europe) | Today, the Annual General Meeting 2026 of Klaria Pharma Holding AB (publ), reg. no. 556959-2917, was held. Below is a summary of the resolutions adopted by the Annual General Meeting (all in accordance... ► Artikel lesen | |
| 05.06. | KLARIA PHARMA HOLDING AB: Klaria Annual Report 2025 | 1 | Cision News | ||
| 05.06. | Klaria Pharma Holding AB: Klaria receives 25 MSEK in loan financing with the possibility of an additional 15 MSEK | 150 | GlobeNewswire (Europe) | Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that Klaria has entered into an agreement for a bridge loan of 25 MSEK from a Swedish finance company. The agreement also includes... ► Artikel lesen | |
| 29.05. | Klaria Pharma Holding AB: Klaria Interim Report Q1 2026 | 176 | GlobeNewswire (Europe) | Klaria Interim Report Q1 2026 1 January - 31 March
Summary of the interim reportFirst quarter of 2026 The group in total - Net sales 0.1 MSEK (9.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D... ► Artikel lesen | |
| 28.05. | KLARIA PHARMA HOLDING AB: Klaria adjusts annual report release date | 1 | Cision News | ||
| 25.05. | Klaria Pharma Holding AB: Summons to the Annual General Meeting of Klaria Pharma Holding AB (publ) | 320 | GlobeNewswire (Europe) | With a change from what has been previously announced, the shareholders of Klaria Pharma Holding AB (publ), corporate registration number 556959-2917, are hereby invited to attend the Annual General... ► Artikel lesen | |
| 22.05. | KLARIA PHARMA HOLDING AB: Klaria postpones interim Q1 report | 1 | Cision News | ||
| KLARIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 21.05. | KLARIA PHARMA HOLDING AB: Klaria postpones publication of the annual report | 2 | Cision News | ||
| 23.04. | Notice of the Annual General Meeting of Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| 05.04. | KLARIA PHARMA HOLDING AB: Annula Genernal Meeting Date Change: Klaria Pharma Holding (publ) | 2 | Cision News | ||
| 19.03. | Correction: Incorrect inclusion of MAR text in earlier release.Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| 19.03. | Klaria Pharma Holding AB: Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ) | 342 | GlobeNewswire (Europe) | Today, an extraordinary general meeting was held in Klaria Pharma Holding AB (publ), company registration number 556959-2917. Below is a summary of the resolutions adopted by the extra general meeting... ► Artikel lesen | |
| 02.03. | Klaria Pharma Holding AB (publ) Summons to Extraordinary General Meeting | 2 | Cision News | ||
| 20.02. | Klaria Pharma Holding AB: Klaria Year-End Report | 727 | GlobeNewswire (Europe) | Klaria Year-End Report Q4 2025
1 January-31 December 2025
SummaryFourth quarter of 2025 The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses for... ► Artikel lesen | |
| 23.12.25 | Klaria Pharma Holding AB: Klaria accelerates its business development work in collaboration with BDO | 866 | GlobeNewswire (Europe) | With Klaria's product, Sumatriptan Alginate Film, approved in the EU and set to launch in 2026 in the largest EU markets, the company has now engaged BDO LLP's UK Life Sciences & Healthcare M&A team... ► Artikel lesen | |
| 17.12.25 | Klaria Pharma Holding AB: Klaria Receives Positive Opinion on Sumatriptan Oral Film Patent Application | 225 | GlobeNewswire (Europe) | Klaria announced earlier in the year that it had submitted an additional patent application on the sumatriptan oral film product to further protect the product and potentially extend its market exclusivity.... ► Artikel lesen | |
| 26.11.25 | Klaria Pharma Holding AB: Klaria Interim Report Q3 2025 | 249 | GlobeNewswire (Europe) | Klaria Interim Report
1 July - 30 September 2025
Summary of the interim reportThird quarter of 2025
The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D... ► Artikel lesen | |
| 28.08.25 | Klaria Pharma Holding AB: Klaria Interim Report Q2 2025 | 365 | GlobeNewswire (Europe) | Klaria interim report
1 April-30 June 2025
Summary of the interim reportSecond quarter of 2025 The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB | 50,34 | -0,14 % | Zelltherapie verlässt das Labor: Warum jetzt die Produktions-Revolution beginnt | ||
| DERMAPHARM | 45,500 | -0,11 % | Dividendenbekanntmachungen (29.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGC INC JP3112000009 105 JPY 0,5701 EUR ALTER EGO MEDIA SA GRS541003000 - 0,03 EUR AOZORA BANK LTD JP3711200000 23 JPY 0,1248... ► Artikel lesen | |
| INCYTE | 101,85 | -0,39 % | Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio | Acquisition adds VGA039, a novel investigational monoclonal antibody in Phase 3 development for patients with von Willebrand disease (VWD), strengthening Incyte's late-stage pipeline
WILMINGTON,... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 6,200 | -0,96 % | Canopy, Tilray & Co. zittern: Lässt die DEA Cannabis-Aktien beben? Darauf sollten Anleger ab Montag achten | © Foto: adobe.stock.comJetzt gilt es für den Cannabis-Sektor: Am Montag startet das Anhörungsverfahren der DEA - für viele Unternehmen geht es dabei um alles.Cannabis - Seit April fährt die DEA zweigleisig... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 11,300 | +0,89 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| OPKO HEALTH | 1,230 | +3,36 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| COSMO | 70,10 | +0,29 % | Cosmo Pharmaceuticals N.V.: Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026 | Dublin, Ireland--(Newsfile Corp. - July 1, 2026) - Cosmo N.V. (SIX: COPN) ("Cosmo") announced today that it will publish its Half-Year 2026 results on Thursday, 23 July 2026 at 7:00 am CEST.... ► Artikel lesen | |
| OXFORD BIOMEDICA | 7,050 | -1,40 % | Oxford Biomedica PLC - Holding(s) in Company | ||
| SUMITOMO PHARMA | 7,695 | +1,04 % | Sumitomo Pharma, Novo Nordisk Win Japan Nod For Wegovy In MASH | TOKYO (dpa-AFX) - Sumitomo Pharma Co., Ltd. (4506.T) announced on Friday that Japan has cleared Wegovy Subcutaneous Injection, which it co-promotes with Novo Nordisk B A/S (NVO), to treat metabolic... ► Artikel lesen | |
| CITIUS PHARMACEUTICALS | 0,583 | 0,00 % | Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | $5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR®
Citius Pharma raised $5 million in a registered direct offering; Citius... ► Artikel lesen | |
| VETOQUINOL | 71,10 | 0,00 % | Dividendenbekanntmachungen (03.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGEAS SA/NV BE0974264930 - 2,25 EUR AMKOR TECHNOLOGY INC US0316521006 0,0835 USD 0,0717 EUR AVERY DENNISON CORP US0536111091 1... ► Artikel lesen | |
| ASTRID INTELLIGENCE | 0,004 | 0,00 % | Astrid Intelligence - Corrective announcement - Directors' Dealing | ||
| BIOHARVEST SCIENCES | 2,440 | -6,87 % | BioHarvest Sciences Inc.: BioHarvest Sciences to Present at the 2026 BIO International Convention | Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable... ► Artikel lesen | |
| OCUMENSION THERAPEUTICS | 0,525 | +7,14 % | OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF OT-502 APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | ||
| BAYER | 50,12 | -1,14 % | Märkte am Morgen: Bayer, Deutsche Bank, SAP, Delivery Hero, Easyjet, ASML | Der DAX hat in der vergangenen Woche abgeliefert. Ein Plus von 4,5 Prozent bedeutet die beste Handelswoche seit April 2025. Vor allem an den letzten Tagen blies der DAX zur Rekordjagd, stellte eine... ► Artikel lesen |
KLARIA PHARMA HOLDING AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,076 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KLARIA PHARMA HOLDING AB finden Sie auf Wallstreet Online.